The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《N-[5-(2-Methoxyethoxy)-2-pyrimidinyl] benzenesulfonamide (glycodiazine). V. Effect of phenylethylbarbituric acid on the metabolism and hypoglycemic effect of glycodiazine in vitro and vivo》. Authors are Gerhards, E.; Kolb, K. H.; Schulze, P. E..The article about the compound:Sodium 4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-idecas:129-18-0,SMILESS:O=C(N(C1=CC=CC=C1)N2C3=CC=CC=C3)[C-](CCCC)C2=O.[Na+]).Name: Sodium 4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-ide. Through the article, more information about this compound (cas:129-18-0) is conveyed.
cf. CA 64, 18224g. The metabolism of glycodiazine, 2-benzenesulfonamido-5-(βhydroxyethoxy)diazine (II), and tolbutamide after Luminal treatment was studied in the rat, dog, and in man. The 20,000 g liver supernatant from untreated rats metabolized 25% of the glycodiazine and tolbutamide in vitro, whereas that fraction from rats treated with Luminal (2 × 5 mg./100 g. body weight/ day for 3 days intraperitoneally) metabolized 60-70% of the drugs. The formation of 2-benzenesulfonamido-5-(carboxymethoxy)diazine from II was increased from 2% with liver fractions from untreated rats to 8% with that from Luminal-treated rats. After oral administration of glycodiazine-3H to untreated rats, 35% of the radioactivity was excreted in the urine within the 1st 4 hrs., whereas Luminal-treated rats excreted 65%. Pretreatment of dogs with Luminal (10 mg./kg./ day for 7 days orally) increased the urinary excretion of 3H following oral administration of 900 mg. of glycodiazine-3H 1.6-fold within 12 hrs., compared with nonpretreated controls. Luminal did reduce the concentration of glycodiazine in the blood, however. In man, pretreatment with Luminal reduced the level of glycodiazine about 2-fold when compared with controls. Luminal did not affect the hypoglycemic effect of glycodiazine in rats, dogs, or humans, indicating that the former has no effect on the influence of the latter on insulin secretion. 23 references.
If you want to learn more about this compound(Sodium 4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-ide)Name: Sodium 4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-ide, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(129-18-0).
Reference:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem